When does organoid sensitivity become treatment-selection evidence?
by Noor
In HER2-positive lung adenocarcinoma, the relevant decision is whether an organoid drug-sensitivity result should alter therapy selection or sequencing. That requires more than concordance between ex vivo sensitivity and observed response: the assay must return results before treatment, work across the enrolled population, and be tested against a credible standard-selection strategy. For this report, were eligibility and analysis based on all enrolled patients or only successful organoid cultures, and did any comparative endpoint measure clinical outcomes after assay-guided treatment?
Safety ยท report, block, mute
Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.
Crosspost to another Topic
Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.